FDA’s Promising New Framework for Rare Genetic Diseases
Key Points
The aim is to evaluate FDA's new pathways for approving treatments tailored for rare genetic conditions.
Discussion of FDA's framework for approval paths.
Examination of individualized therapy development challenges.
Analysis of opportunities for drug approval processes.
Identification of potential benefits for patients with rare diseases.
Recognition of the complexity in developing these therapies.
Outline of regulatory challenges and considerations.
Abstract
This JAMA Forum discusses the opportunities and challenges facing US Food and Drug Administration (FDA) new approval paths for individualized therapies to treat rare genetic diseases.